**Table 2: Medlicott & Harris15 Evaluation of Methodological Rigor in Descending Order of Methodical Rigor**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author and Year of Publication** | **Randomization** | **Subject Inclusion**  **Exclusion**  **Criteria** | **Similarity at Baseline** | **Repeatability of the Treatment Protocol** | **Outcome Measure Reliability** | **Outcome Measure Validity** | **Blind Assessment** | **Account for Attrition** | **Long-term Follow up** | **Adherence to a Home Program** | **Total Rigor Score15** | **Level**  **of Evidence** |
| Jones et al 201229 | Y | Y | Y | Y | Y (3/4) | Y (3/4) | Y (D) | Y | N | Y | 7.8/10 | IIA |
| Linden et al 201333 | Y | Y | Y | Y | Y (1/2) | Y (1/2) | Y (D) | Y | N | N/A | 6.3/9 | IIA |
| Jones et al 200328 | N | N | N | Y | Y | Y | N | Y | N | Y | 5/9 | IVA |
| Chen X et 201419 | Y | N | Y | Y | N | N | N | Y | N | N/A | 4/9 | IIA |
| Inman et al 201127 | Y | N | Y | Y | N | N | N | Y | N | N/A | 4/9 | IIA |
| Marchal-Crespo et al 201037- RCT | Y | N | Y | Y | N | N | N | Y | N | N/A | 4/9 | IIA |
| Dunaway et al 201321 | N | N | N | Y | Y (1/2) | Y (1/2) | N | Y | N | Y | 4/9 | IVA |
| Logan et al 201434 | N | N | N | Y | Y (3/4) | Y (1/4) | N | Y | N | Y | 4/10 | VB |
| Huang et al 201425 | N | N | N | Y | Y (1/3) | Y (1/3) | N | Y | N | Y | 3.6/9 | IVA |
| Lynch et al 200936 | N | N | N | Y | Y | Y (1/2) | N | Y | N | N/A | 3.5/9 | IVA |
| Kenyon et al 201530 | N | N | N | Y | Y (2/3) | Y (2/3) | N | Y | N | N/A | 3.3/9 | IVA |
| Kenyon et al 201631 | N | N | N | Y | Y (2/3) | Y (2/3) | N | Y | N | N/A | 3.3/9 | IVA |
| Huang et al 201526 | N | Y | N | Y | N | N | N | Y | N | N/A | 3/9 | IIIA |
| Butler et al 198418 | N | N | N | Y | N | N | N | Y | N | Y | 3/9 | IVA |
| Douglas & Ryan 198720 | N | N | N | Y | N | N | N | Y | Y | N/A | 3/9 | IVA |
| Furumasu et al 199622 | N | N | N | Y | Y | N | N | Y | N | N/A | 3/9 | IVA |
| McGarry et al 201238 | N | Y | N | Y | N | N | N | Y | N | N/A | 3/9 | IVA |
| Montesano et al 201039 | N | Y | N | Y | N | N | N | Y | N | N/A | 3/9 | IVA |
| Ragonesi et al 201140 | N | N | N | Y | Y | N | N | Y | N | N/A | 3/9 | IVA |
| Ragonesi et al 201241 | N | N | N | Y | Y | N | N | Y | N | N | 3/9 | IVA |
| Logan et al 201635 | N | N | N | Y | Y | N | N | Y | N | N/A | 3/9 | VB |
| Adelola et al 200917 | N | N | N | Y | N | N | N | Y | N | N/A | 2/9 | IVA |
| Galloway et al 200823 | N | N | N | Y | N | N | N | Y | N | N/A | 2/9 | IVA |
| Harrison et al 200224 | N | N | N | Y | N | N | N | Y | N | N/A | 2/9 | IVA |
| Larin et al 201232 | N | N | N | Y | N | N | N | Y | N | N/A | 2/9 | IVA |
| Marchal-Crespo et al  201037 –Case report | N | N | N | Y | N | N | N | Y | N | N/A | 2/9 | IVA |
| Zeng et al 200942 | N | N | N | Y | N | N | N | Y | N | N/A | 2/9 | IVA |

D: data collectors blinded; N: study design attribute absent; N/A: not applicable (used for the home program criterion only); S: subject blinded; Y: study design attribute present.

A Level of evidenced determined using the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence13

B Level of evidence determined using the Levels of Evidence for Single-Subject Research Designs14